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Abstract
The haem proteins TDO (tryptophan 2,3-dioxygenase) and IDO (indoleamine 2,3-dioxygenase) are speciﬁc
and powerful oxidation catalysts that insert one molecule of dioxygen into l-tryptophan in the ﬁrst and rate-
limiting step in the kynurenine pathway. Recent crystallographic and biochemical analyses of TDO and IDO
have greatly aided our understanding of the mechanisms employed by these enzymes in the binding and
activation of dioxygen and tryptophan. In the present paper, we brieﬂy discuss the function, structure
and possible catalytic mechanism of these enzymes.
Introduction
Haem-containing proteins have a wide variety of functions
ranging from oxygen transport, storage and activation to
simple single-electron transfers. TDO (tryptophan 2,3-
dioxygenase) and IDO (indoleamine 2,3-dioxygenase) are
members of a small family of haem enzymes that catalyse the
aerobicmetabolismof L-tryptophantoN-formylkynurenine.
TDO was initially discovered in the 1930s and is found in
both eukaryotes and prokaryotes [1]. TDO expression is
normally restricted to the liver in mammals, although it has
been identified in the brain and epididymis of some species
[2,3]. IDO was first isolated from rabbit intestine in 1967
[4], and is found in many eukaryotes where it is expressed
ubiquitously throughout the body, except in the liver. Some
prokaryotic IDO-like proteins from Shewanella species have
beenidentified[5],but todate thesehavenoknownfunction.
Sequence similarity between family members is low, with
amino acid sequence alignment indicating an identity of
approx. 10% between family members. Homology is only
apparent from their three-dimensional structures and the
conservation of certain amino acids in their active sites.
Why are TDO and IDO of interest?
A vital biochemical reaction
TDO and IDO activate molecular oxygen and catalyse its
insertion into L-tryptophan to form N-formylkynurenine, in
the first and rate-limiting step in the kynurenine pathway
[6]. The kynurenine pathway processes over 90% of L-tryp-
tophan utilized by humans. Although both enzymes
catalyse the same reaction, TDO is highly substrate-specific,
only dioxygenating L-tryptophan and some tryptophan
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derivatives substituted in the 5- and 6-positions. IDO
displays wider substrate specificity, catalysing the dioxygen-
ationof D-tryptophan,tryptamineand5-hydroxytryptamine
(serotonin) in addition to those substrates dioxygenated by
TDO [7].
Tryptophan regulation
Both TDO and IDO play a central role in the regulation of
tryptophan in the human body, controlling the kynurenine
pathway and influencing serotogenic regulation [8]. IDO
and TDO activity alters local tryptophan concentra-
tion and the build-up of pathway metabolites can lead to
numerous physiological and pathophysiological conditions.
These include cataract formation, AIDS-related dementia
and ischaemic brain injury [6,8–10]. In addition, the local
depletion of tryptophan by IDO or TDO is associated
with an antimicrobial response. Some pathogens are sensitive
to tryptophan degradation, and this may be an effective
mechanism for controlling their ability to proliferate [11].
Immune regulation
Although both enzymes catalyse the same reaction, compart-
mentalization of IDO and TDO expression is thought to
reflect their differing biological roles. IDO plays an active
role in the human body’s immune response, but there is
little evidence to suggest that TDO plays a part in this
process. Immune regulation by IDO is extremely complex,
but two major roles have become evident [12,13]. First,
IDO is a normal effector of peripheral tolerance in the
immunoregulatory pathway of tryptophan metabolism. It
helps to create an appropriate immune response, influenc-
ing the balance between tolerance and attack. Secondly, it
is thought to play an essential role in acquired immune
tolerance. IDO helps tumours to induce tolerance from
the host’s immune system by interacting with T-cells and
depleting L-tryptophan levels [13], and it has consequently
emerged as an attractive drug target in cancer and transplant
treatments.
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Figure 1 Structures of (a)x c T D Oa n d( b) hIDO
(a) Structure of xcTDO. l-Tryptophan is shown in red, haem is grey, and separate monomers are shown in cyan, magenta,
grey and blue. (b) Structure of hIDO. Haem is shown in grey, the smaller N-terminal domain is shown in grey, and the larger
C-terminal domain is shown in marine.
TDO and IDO structures?
Overall structure
Recent crystallographic studies of xcTDO (Xanthomonas
campestris TDO) [5], rmTDO (Ralstonia metallidurans
TDO) [14] and hIDO (Homo sapiens IDO) [15] have aided
our understanding of this family of haem enzymes. The
crystal structures of xcTDO and rmTDO are essentially
identical, sharing 47% sequence identity, and are intimately
associated homotetrameric enzymes (Figure 1a). They are
perhaps best described as a dimer of dimers because the N-
terminalresiduesofeachmonomerformpartofthesubstrate-
binding site in an adjacent monomer. The N-terminal region
lies above the distal face of the haem, providing part of
the binding cavity. The proteins are completely helical, and
a flexible loop (comprising residues 250–260 of xcTDO),
involved in L-tryptophan binding, is observed just outside
the haem pocket. This loop is only ordered in crystals grown
in the presence of L-tryptophan, as substrate binding appears
to induce its ordering.
IDO is a monomeric protein, folded into two distinct do-
mains: a large (C-terminal) domain and a small (N-terminal)
capping domain (Figure 1b). Contact between these domains
is extensive, and they are joined by a long loop. The larger
domain is essentially topologically identical with a monomer
ofTDO,andthestructuresarereadilysuperposable[5,14,15].
Theloopregionconnectingthetwodomainsprovidessimilar
interactions in the active site to those provided by the N-
terminal arm of TDO, forming part of the active-site cavity.
A flexible loop exists just outside the haem pocket, like
that of TDO, but is not fully resolved crystallographically,
probably due to the lack of bound substrate in the active
site.
Active-site environment
TDO and IDO are b-type haem proteins with histidine
occupying the axial co-ordination position to the haem iron.
The only structure available with substrate bound at the
active site in the catalytically active ferrous state is xcTDO.
The structure clearly shows the important substrate-binding
interactions in the active site. The active-site pockets of
xcTDO with and without L-tryptophan bound and that of
hIDO are shown in Figure 2. Owing to high similarity
between the active sites of TDO and IDO, it is reasonable to
assumeasimilarsubstrate-bindingmodeinIDO.Interactions
of the substrate with the active site can be split into two cat-
egories:interactionswiththecarboxyandammoniumgroups
of L-tryptophan, and those with the indole ring system.
In the structure of xcTDO, the carboxy group of L-
tryptophan interacts with Arg117,T y r 113 and Thr254. Amino
acid residues equivalent to Arg117 and Tyr113 are found in
nearly all TDO and IDO proteins. This carboxy-binding
motif appears to be essential for substrate binding; arginine
reorients in the presence of substrate, co-ordinating the
carboxy group of L-tryptophan with both ‘open’ and ‘closed’
conformations observed (Figures 2a and 2b). The closed con-
formation is only observed in TDO crystals grown in the
presence of L-tryptophan. The substrate ammonium group
is hydrogen-bonded to the side-chain hydroxy group of
Thr254, the 7-propionate group of the haem, and a water
molecule. Thr254 is involved in binding both the ammonium
and carboxy moieties of L-tryptophan and is part of the
flexible loop, just outside the haem pocket.
Thesubstrateindoleringbindsintoahydrophobicpocket,
where it interacts with the side chain of Phe51 and several
other hydrophobic residues, including Tyr24 and Tyr27 from
the adjacent monomer. Both of these tyrosine residues
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Figure 2 Active-site residues of xcTDO and hIDO
Active-site residues of (a) substrate-free xcTDO, (b) l-tryptophan-bound xcTDO, with l-tryptophan shown in red, and
(c) hIDO, with 4-phenylimidazole (shown in red) bound.
Figure 3 Proposed catalytic mechanism of IDO and TDO
Initial formation of the ternary complex (1) occurs by substrate binding to the ferrous protein, followed by dioxygen binding.
The ternary complex activates O2 and catalysis proceeds via the formation of a hydroperoxide intermediate (2 and 5)t h a t
undergoes either a Criegee or a dioxetane rearrangement to form the product N-formylkynurenine (7).
are hydrogen-bonded to a glutamate residue, linking the
N-terminal loop of the adjacent monomer to the active site,
and this Tyr-Glu motif is conserved throughout TDO and
IDO proteins.
Perhaps the most obvious difference between the active
sites of TDO and IDO is the presence of His55 in xcTDO
and its equivalent, Ser167 in hIDO (Figure 2). In TDO, the
histidine side chain is hydrogen-bonded with the NH group
of the indole ring of L-tryptophan, and a role for His55 would
appear to be in regulating substrate binding. In comparison,
Ser167 inIDOisincapableofformingthisbond,anditappears
unlikely that this residue plays any critical role in substrate
binding or catalysis by IDO.
What is the catalytic mechanism?
Substrate binding
The proposed catalytic mechanism employed by this family
ofenzymesisshowninFigure3.Itisthoughtthattheferrous
enzyme is required for catalytic activity and, upon substrate
binding, there is an increase in the electrochemical midpoint
potential for both TDO and IDO. This shift in the reduc-
tion potential reflects additional stabilization of the ferrous
form.Suchathermodynamicstabilizationofthereducedform
would clearly favour reduction before substrate binding
[5,16–18]. A recent study has suggested that cytochrome b5
is the electron transfer partner for IDO, providing ferrous
active protein in vivo, consistent with these results.
For TDO, the initial formation of the ternary complex
(Figure 3, 1) occurs by substrate binding followed by
dioxygen binding to the ferrous protein. For IDO, the order
of binding events is more complex, but the ternary complex
must still be formed before the reaction can proceed. The
ternary complex activates O2 and allows the otherwise spin-
forbidden reaction to proceed.
Formation of the hydroperoxide intermediate
It has been proposed that formation of the hydroperoxide
intermediate (Figure 3, 2 and 5) is catalysed by the loss
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of the indole proton. Two mechanisms are thought to be
probable:base-catalyseddeprotonationorprotonabstraction
by bound dioxygen [7]. If the substrate-binding mode
in IDO is similar to that seen in xcTDO, proton
abstraction by a proteinaceous base is only possible in
TDO, with the active-site histidine (His55 in xcTDO)
being the only basic residue in the active site of either
enzyme (Figure 2). However, catalytic activity is main-
tained upon substitution of alanine for His55 in xcTDO,
suggesting that base-catalysed deprotonation may not be
essential for enzymatic activity [5]. Catalysis by the iron-
bounddioxygenisgenerallyproposedforIDOintheabsence
of a base, and seems reasonable from modelling simulations.
Rearrangement of the hydroperoxide
intermediate
The rearrangement of the hydroperoxide intermediate to
form the product could occur via either a Criegee or a
dioxetane intermediate [7]. Little biochemical information
currently exists to discriminate between these two differ-
ing pathways, and all discussion has been based on
thermodynamic considerations and computer modelling
simulations [7,14]. Thermodynamic considerations indicate
that formation of the highly strained dioxetane intermediate
and its high exothermicity of decomposition make this an
unlikely route to be employed by an enzyme. In addition,
no chemiluminescence has been detected on decomposition
of the dioxetane. These data alone support the Criegee
rearrangement for both IDO and TDO. However, further
investigation is necessary to determine the nature of this
rearrangement.
Conclusion
Recent crystallographic and biochemical analyses of TDO
and IDO have aided our understanding of the mechanisms
employed for binding and activating dioxygen by allowing
identification of key active-site residues. Analysis of the
active-sitepocketsofTDOandIDOshowsthattherearedif-
ferencesinthechoiceofresiduesemployedincatalysis.How-
ever, how these changes have an impact on the catalytic
mechanism and reaction intermediates employed by these
enzymes is still unclear. Recent studies have led to possible
future routes of investigation. These include: substitution
of newly identified key active-site residues to identify their
rolesincatalysis;EPRandENDOR(electronnucleardouble
resonance) studies of reaction intermediates, and computer
modelling simulations.
Note added in proof (received
23 September 2008)
In a recent article by Chung et al. [19], density functional
theory calculations on the catalytic mechanism of TDO
and IDO have cast doubt on the relevance of the Criegee
mechanism and raised the possibility of a radical addition
pathway.
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